

SPONSORED BY



BUPRENORPHINE CERTIFICATION COURSE

March 4th, 2022

REGISTER ONLINE at <https://www.eeds.com/byinviteonly/344981>

Participation in this course is free.

This is a virtual course. Online meeting room information will be emailed to all who register. Please complete registration prior to 5 p.m. Monday, February 28th.

For more information contact Karletta Pergeson at kpergeson@kumc.edu.

PROGRAM

PRESENTED BY

12:30 p.m.	Overview: Opioid Use Disorder Treatment with Buprenorphine/Naloxone
1:15 p.m.	Patient Evaluation
2:00 p.m.	Specialty Topics
2:45 p.m.	Case Study #1
3:00 p.m.	Break
3:15 p.m.	Medication Assisted Treatment Clinical Application
3:45 p.m.	Case Study #2
4:00 p.m.	Urine Drug Testing
4:30 p.m.	Case Study #3
4:45 p.m.	Overview of Clinical Tools
5:00 p.m.	Completing the Notification of Intent Waiver Form

Daniel Warren, MD
Assistant Professor
KUSM-Wichita
Dept. of Family & Community Medicine

This seminar will specifically focus on buprenorphine treatment of opioid use disorder in an office-based setting. The standard Provider Clinical Support System (PCSS) will be presented and will qualify for the first half of training to receive the DATA 2000 buprenorphine waiver.



OBJECTIVES

At the conclusion of this symposium the participant will be able to:

- describe regulations for buprenorphine treatment of opioid use disorder
- discuss how buprenorphine's unique pharmacology affects its clinical use
- explain the risks of buprenorphine diversion and misuse
- present data related to buprenorphine treatment outcomes and side effects, with comparison to methadone
- perform a typical history and physical appropriate to buprenorphine induction
- diagnose opioid use disorder and comorbid substance use and psychiatric disorders
- explain potential contraindications to buprenorphine treatment
- provide a detailed description of the buprenorphine induction process
- discuss typical practice for buprenorphine maintenance
- compare naltrexone with buprenorphine for specific patient populations

The AAFP has reviewed Buprenorphine Certification Course, and deemed it acceptable for AAFP credit. Term of approval is from 04/30/2021 to 04/30/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit approval includes the following session(s):

4.25 Online Only, Live AAFP Prescribed Credit(s) - Buprenorphine Certification Course

This workshop has been funded by a grant from the Kansas Department of Health and Environment through the Centers for Disease Control and Prevention under Federal Award Identification Number 1 NU17CE924998-01-00.